Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
NCT00519532
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
84
Enrollment
INDUSTRY
Sponsor class
Stopped
Due to clinical trial supplies shortage
Conditions
Parkinson's Disease
Interventions
DRUG:
Rotigotine
Sponsor
UCB Pharma